Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBT 986 in Healthy Volunteers with LPS-Induced Coagulation
NCT02259881Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2002
- Primary completion
- May 2003
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of tanogitran in thromboembolism (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Activated Partial Thromboplastin Time up to 48 hours, International Normalized Ratio up to 48 hours and 21 more. Started Dec 2002; status: completed.
02
Drugs
tanogitran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02259881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259881.